In our recently released 2024 annual results, Henlius has achieved profitability for the second consecutive year, marking another milestone in our journey. With revenue reaching RMB 5.724 billion and net profit surging by 50.3% year-on-year, we continue to lead the industry. Our six approved products have now benefited over 750,000 patients worldwide, underscoring the success of our dual strategies of "Innovation" and "Globalization".

Today, Henlius' global presence spans more than 50 countries and regions, driven by our core philosophy of "Collaborate to Create". This approach has enabled us to drive technological advancements and transform the healthcare ecosystem. In 2025, we will further power our innovation engine, making continuous breakthroughs in technology platforms while fostering explosive growth in our differentiated pipeline. We are strategically advancing cutting-edge technologies to accelerate the delivery of more affordable and transformative solutions for patients, ensuring the efficientt transformation of technological expertise into clinical value.

As we enter a new phase of innovation and strategic evolution, we are excited to announce the 2025 Global R&D Day, to be held on April 15, 2025, in Shanghai.

This event will showcase our latest advancements in R&D, future strategic plans, and pioneering technologies and therapies. It will also serve as a platform for in-depth discussions with top industry experts, R&D leaders, investors, and other key stakeholders.

We look forward to your presence and to exploring the future of innovation together.